The Sigma Non Opioid Intracellular Receptor 1 pipeline drugs market research report outlays comprehensive information on the Sigma Non Opioid Intracellular Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Sigma Non Opioid Intracellular Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Genetic Disorders, and Ophthalmology which include the indications Alzheimer’s Disease, Parkinson’s Disease, Stroke, Systolic Hypertension, Fragile X Syndrome, Tuberous Sclerosis, Ophthalmology, and Glaucoma. It also reviews key players involved in Sigma Non Opioid Intracellular Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Sigma Non Opioid Intracellular Receptor 1 pipeline targets constitutes close to 31 molecules. Out of which, approximately 27 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 4, 2, 4, 2, 12, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 2 molecule.
Sigma Non Opioid Intracellular Receptor 1 overview
Sigma non-opioid intracellular receptor 1 (SIGMAR1) is a chaperone protein in the endoplasmic reticulum that regulates calcium signaling. It functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions, probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. SIGMAR1 is involved in the regulation of different receptors; it plays a role in BDNF signaling and EGF signaling, it regulates ion channels like the potassium channel and could modulate neurotransmitter release.
For a complete picture of Sigma Non Opioid Intracellular Receptor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
